Synthesis, characterization, and in silico and in vivo profiling of selective cyclo-oxygenase-2 inhibitors of indazole–indolinone derivatives with anti-inflammatory and analgesic potency

TL;DR

This paper presents new indazole-indolinone compounds with strong anti-inflammatory and pain-relieving effects, showing promise as safer alternatives to traditional NSAIDs.

Contribution

The study introduces novel COX-2 selective inhibitors with high analgesic and anti-inflammatory potency confirmed through in silico and in vivo experiments.

Findings

Compound AB 12 showed strong binding to COX-2 with a binding energy of -9.6 kcal/mol.

AB 12 demonstrated significant analgesic and anti-inflammatory effects in preclinical models.

Molecular dynamics simulations confirmed the stability of AB 12 and COX-2 interactions over 50 ns.

Abstract

The intensive use of non-steroidal anti-inflammatory and analgesic drugs (NSAIDS) worldwide poses a challenge to scientists because of the adverse side effects. This article aims to synthesize a novel group of 1-aminoindazole-isatin Schiff base compounds considering their potency as analgesic and anti-inflammatory agents.

The synthesis of novel agents involved reflux condensation of isatin derivatives (5 mmol) and 1-aminoindazole (5 mmol) in ethanol for 2 h, which were then characterized for their structural integrity. In silico evaluation using PyRx, BIOVIA Discovery Studio, and GROMACS was performed to determine the affinity of the specific receptors and compare them with the results gained by use of standard diclofenac before preclinical evaluation using albino mice (analgesic activity) and rats (anti-inflammatory activity). The preclinical analgesic potency was analyzed via Eddy’s hot plate and tail-pin methods, whereas, the anti-inflammatory potency was analyzed through carrageenan-induced paw edema against diclofenac as the standard agent.

A high percentage yield of the reactions was determined (≈80%); the IR, NMR, and mass spectra showed the compounds to be stable with no shifts, justifying the accuracy of the procedure employed. The molecular docking of the ligands with two different crystal structures of proteins of interest, i.e., COX-1 and COX-2, yielded stable and the lowest binding energies, i.e., −9.6 kcal/mol for AB 12 and – 7.1 kcal/mol for diclofenac. Through molecular dynamic simulations employing GROMACS for a time period of 50 ns, AB 12 and diclofenac also yielded a thermodynamically stable and structurally folded protein and ligand complex, showing an average of 0–3 (AB 12) and 0–5 (diclofenac) hydrogen bonds with the least system fluctuations and atom deviations; furthermore, the potential energy of the complete system was stabilized at an average point of – 685,000 kj/mol for both molecules. The preclinical results showed a significant value for the ligand AB 12 (p ≤ 0.01) against the diseased control group.

The ligand AB 12, AB 14 and AB 15 is exceptional as an analgesic and anti-inflammatory agent. AB 12 further showed stable hydrogen bonds with protein COX-2 for 50 ns in comparison with diclofenac. Based on this study, these molecules can be considered best for future studies regarding the toxicological profile.

Figures